Phreesia, Inc. (NYSE:PHR) Insider Sells $16,296.00 in Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 582 shares of the stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $28.00, for a total value of $16,296.00. Following the sale, the insider now owns 31,010 shares in the company, valued at approximately $868,280. This represents a 1.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Yvonne Hui also recently made the following trade(s):

• On Monday, April 21st, Yvonne Hui sold 993 shares of Phreesia stock. The shares were sold at an average price of $23.04, for a total transaction of $22,878.72.
• On Tuesday, April 15th, Yvonne Hui sold 314 shares of Phreesia stock. The stock was sold at an average price of $24.04, for a total transaction of $7,548.56.
• On Tuesday, April 8th, Yvonne Hui sold 1,878 shares of Phreesia stock. The shares were sold at an average price of $23.85, for a total transaction of $44,790.30.

Phreesia Trading Down 0.6%

PHR stock traded down $0.17 during midday trading on Friday, hitting $26.45. The company had a trading volume of 157,567 shares, compared to its average volume of 442,449. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -17.97 and a beta of 0.68. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock's 50 day moving average price is $24.97 and its 200 day moving average price is $25.69.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. During the same quarter in the prior year, the company posted ($0.05) EPS. The firm's revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, equities research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PHR. Charles Schwab Investment Management Inc. raised its holdings in shares of Phreesia by 10.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock valued at $12,415,000 after acquiring an additional 46,209 shares in the last quarter. Barclays PLC raised its holdings in Phreesia by 83.6% in the 3rd quarter. Barclays PLC now owns 94,929 shares of the company's stock worth $2,163,000 after purchasing an additional 43,225 shares in the last quarter. Deutsche Bank AG raised its holdings in Phreesia by 95.9% in the 4th quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock worth $1,442,000 after purchasing an additional 28,047 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Phreesia in the 4th quarter worth about $377,000. Finally, M&T Bank Corp boosted its stake in shares of Phreesia by 56.4% during the 4th quarter. M&T Bank Corp now owns 54,939 shares of the company's stock valued at $1,382,000 after purchasing an additional 19,812 shares in the last quarter. Institutional investors own 92.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PHR. DA Davidson decreased their target price on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. KeyCorp dropped their target price on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Canaccord Genuity Group lowered their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research report on Thursday, May 29th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research report on Thursday, March 13th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $31.64.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.